FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM).
Grommes C, Karimi S, Beal K, Chan T, Abrey L, Gutin P, Omuro A. FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM). Journal Of Clinical Oncology 2011, 29: 2048-2048. DOI: 10.1200/jco.2011.29.15_suppl.2048.Peer-Reviewed Original Research